14:20 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

The OXPHOS complex I inhibitor IACS-010759 for mantle cell and B cell lymphoma

DISEASE CATEGORY: Cancer INDICATION: Mantle cell lymphoma (MCL); B cell lymphoma Patient sample, cell culture and mouse studies identified an OXPHOS complex I inhibitor that could help treat MCL and B cell lymphoma that are...
19:41 , May 16, 2019 |  BC Extra  |  Company News

Genentech adds to autoimmune pipeline with Parvus deal

In its second deal based on its immunomodulatory platform, Parvus granted Genentech rights to develop and commercialize its Navacim nanoparticle therapeutics to treat inflammatory bowel disease (IBD), autoimmune liver diseases and celiac disease. Parvus Therapeutics...
22:42 , May 15, 2019 |  BC Extra  |  Clinical News

May 15 Clinical Quick Takes: Principia, Agios, Y-mAbs, Pfizer

Principia gets $30M from Sanofi for Phase IIb MS trial start  Principia Biopharma Inc. (NASDAQ:PRNB) said partner Sanofi (Euronext:SAN; NASDAQ:SNY) began a Phase IIb trial of SAR442168 to treat relapsing multiple sclerosis, triggering a $30...
00:16 , May 14, 2019 |  BC Extra  |  Financial News

Trade tensions sink biotech shares as markets skid

While biopharma products have largely escaped Beijing and Washington’s tariff lists, biotech indexes were dragged down with the rest of the U.S. market Monday as the U.S. and China escalated their trade war. But industry...
18:22 , May 7, 2019 |  BC Extra  |  Clinical News

May 7 Clinical Quick Takes: AZ, Merck, Osmotica, AlzeCure

AZ's Calquence meets in Phase III for CLL  AstraZeneca plc (LSE:AZN; NYSE:AZN) said an interim analysis of the Phase III ASCEND trial to treat relapsed or refractory chronic lymphocytic leukemia showed that Calquence acalabrutinib as...
23:04 , Apr 17, 2019 |  BC Extra  |  Financial News

Biotech indexes tumble in preview of campaign volatility

Biotech indexes tumbled on Wednesday as presidential primary rhetoric weighed on biopharma shares. The rout came a day after UnitedHealth Group Inc. (NYSE:UNH) CEO David Scott Wichmann waded into the Medicare For All debate, sending...
19:55 , Apr 11, 2019 |  BC Innovations  |  Emerging Company Profile

Nurix: Two sides of protein degradation

Nurix is flipping the concept of targeted protein degradation on its head. In addition to the usual approach of inducing target destruction, the company has technology that can block E3 ligase activity and increase a...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
17:35 , Mar 15, 2019 |  BC Week In Review  |  Company News

Principia reacquires immunoproteasome inhibitors from AbbVie

Principia and AbbVie agreed to end a 2017 deal to develop oral immunoproteasome inhibitors to treat autoimmune disorders. Principia Biopharma Inc. (NASDAQ:PRNB), which regained rights to the program, said AbbVie Inc. (NYSE:ABBV) had determined that...
16:49 , Mar 12, 2019 |  BC Extra  |  Politics & Policy

NCI’s Sharpless to become acting FDA commissioner

Ned Sharpless, director of the National Cancer Institute, will serve as acting FDA commissioner when Scott Gottlieb leaves the agency in mid-April. Speaking at a congressional hearing Tuesday, HHS Secretary Alex Azar announced that Douglas...